PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
65.60%
Positive revenue growth while CRON.TO is negative. John Neff might see a notable competitive edge here.
109.55%
Positive gross profit growth while CRON.TO is negative. John Neff would see a clear operational edge over the competitor.
77.73%
EBIT growth below 50% of CRON.TO's 368.92%. Michael Burry would suspect deeper competitive or cost structure issues.
77.73%
Positive operating income growth while CRON.TO is negative. John Neff might view this as a competitive edge in operations.
115.00%
Positive net income growth while CRON.TO is negative. John Neff might see a big relative performance advantage.
115.13%
Positive EPS growth while CRON.TO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
114.87%
Positive diluted EPS growth while CRON.TO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.41%
Share reduction more than 1.5x CRON.TO's 2.07%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
1.04%
Diluted share count expanding well above CRON.TO's 1.64%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
14.93%
Positive OCF growth while CRON.TO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
21.35%
Positive FCF growth while CRON.TO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1088.27%
3Y revenue/share CAGR 1.25-1.5x CRON.TO's 731.27%. Bruce Berkowitz might see better product or regional expansions than the competitor.
-5491.93%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-3771.73%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-1815.90%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
1243.82%
Net income/share CAGR above 1.5x CRON.TO's 340.45% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
413.21%
5Y net income/share CAGR 1.25-1.5x CRON.TO's 340.45%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
272.91%
Below 50% of CRON.TO's 1880.60%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
5974.97%
10Y equity/share CAGR above 1.5x CRON.TO's 2456.21%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
13212.67%
5Y equity/share CAGR above 1.5x CRON.TO's 2456.21%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
1278.80%
3Y equity/share CAGR at 50-75% of CRON.TO's 2428.39%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
27.87%
AR growth is negative/stable vs. CRON.TO's 138.23%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
3.14%
We show growth while CRON.TO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
15.58%
Asset growth above 1.5x CRON.TO's 0.17%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-2.05%
We have a declining book value while CRON.TO shows 5.59%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
513.53%
Debt growth far above CRON.TO's 15.24%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
14.17%
R&D dropping or stable vs. CRON.TO's 134.00%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-22.82%
We cut SG&A while CRON.TO invests at 36.10%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.